



**TITAN LOGIX CORP.**

**FISCAL 2025 THIRD QUARTER FINANCIAL REPORT**

**UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the three- and nine-months ended May 31<sup>st</sup>, 2025**

**Notice of Reader of Interim Condensed Consolidated Financial Statements**

These interim condensed consolidated financial statements and related notes for the period ended May 31, 2025, have been prepared by and are the responsibility of management of Titan Logix Corp. The auditors of Titan Logix Corp. have not audited or reviewed these interim condensed consolidated financials.

	May 31 2025	August 31 2024
	\$	\$
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents (note 5)	7,734	3,292
Short term investments (note 5)	5,000	7,781
Accounts receivable	847	1,345
Inventories	2,282	1,726
Prepaid expenses	90	200
Marketable securities (note 6)	329	715
<b>Total current assets</b>	<b>16,282</b>	<b>15,059</b>
<b>Non-current assets</b>		
Limited recourse capital notes (note 7)	-	1,860
Property, plant and equipment	136	151
Right-of-use assets	581	687
Intangible assets	928	541
Deferred tax assets	674	724
<b>Total assets</b>	<b>18,602</b>	<b>19,022</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities	790	736
Income tax payable	6	51
Current portion of lease obligations	141	133
<b>Total current liabilities</b>	<b>937</b>	<b>920</b>
<b>Non-current liabilities</b>		
Lease obligations	494	600
<b>Total liabilities</b>	<b>1,431</b>	<b>1,520</b>
<b>Shareholders' equity</b>		
Share capital (note 8)	5,686	5,730
Treasury shares	(1)	-
Contributed surplus	1,076	990
Retained earnings	10,411	10,782
<b>Total shareholders' equity</b>	<b>17,171</b>	<b>17,502</b>
<b>Total liabilities and shareholders' equity</b>	<b>18,602</b>	<b>19,022</b>

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

On behalf of the Board

"Helen Cornett"  
Director

"Grant Reeves"  
Director



**Condensed Consolidated Interim Statement of Net and Comprehensive Earnings (Loss)**

(unaudited - In 000's of CAD \$ excluding per share amount, except where otherwise noted)

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Revenue (note 14)</b>	<b>1,489</b>	<b>1,926</b>	<b>5,145</b>	<b>5,191</b>
<b>Cost of sales</b>	<b>(782)</b>	<b>(922)</b>	<b>(2,510)</b>	<b>(2,584)</b>
<b>Gross profit</b>	<b>708</b>	<b>1,004</b>	<b>2,635</b>	<b>2,606</b>
<b>Expenses</b>				
Selling, general and administrative expenses	(534)	(595)	(1,735)	(1,723)
Engineering, product research and development expenses	(433)	(333)	(1,088)	(949)
Depreciation of property, plant and equipment	(9)	(10)	(26)	(27)
Depreciation of right-of-use assets	(16)	(17)	(47)	(46)
Amortization of intangible assets	(51)	(51)	(152)	(146)
Gain (loss) on foreign exchange	(53)	4	(2)	39
<b>Total expenses</b>	<b>(1,095)</b>	<b>(1,002)</b>	<b>(3,051)</b>	<b>(2,851)</b>
Operating income (loss) before other items	(388)	2	(416)	(245)
<b>Other items</b>				
Unrealized loss on marketable securities (note 6)	(120)	(424)	(112)	(728)
Unrealized gain (loss) on limited recourse capital notes	-	35	-	102
Realized gain on sale of financial instruments	-	-	41	-
Finance income (note 9)	114	183	394	534
Interest on leases	(12)	(14)	(37)	(42)
Loss on disposal of property, plant and equipment	-	-	(11)	(1)
Total other items	(18)	(221)	276	(134)
<b>Loss before income taxes</b>	<b>(405)</b>	<b>(218)</b>	<b>(141)</b>	<b>(378)</b>
<b>Income tax expense</b>	<b>(15)</b>	<b>-</b>	<b>(84)</b>	<b>-</b>
<b>Net and comprehensive loss</b>	<b>(421)</b>	<b>(218)</b>	<b>(225)</b>	<b>(378)</b>
<b>Loss per share (note 11)</b>				
Basic and diluted	(0.01)	(0.01)	(0.01)	(0.01)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

	Common Shares #	Share Capital \$	Contributed Surplus \$	Treasury Shares \$	Retained Earnings \$	Total Shareholders' Equity \$
Balance at August 31, 2024	28,536,132	5,730	990	-	10,782	17,502
Share-based compensation (note 8)	-	-	96		-	96
Exercise of stock options (note 8)	18,241	11	(11)		-	-
Repurchase of common shares (note 8)	(274,000)	(55)		(1)	(146)	(202)
Net loss	-	-	-		(225)	(225)
<b>Balance at May 31, 2025</b>	<b>28,280,373</b>	<b>5,686</b>	<b>1,076</b>	<b>(1)</b>	<b>10,411</b>	<b>17,171</b>

  

	Common Shares #	Share Capital \$	Contributed Surplus \$		Retained Earnings \$	Total Shareholders' Equity \$
Balance at August 31, 2023	28,536,132	5,730	912		10,236	16,878
Share-based compensation (note 8)	-	-	55		-	55
Net loss	-	-	-		(378)	(378)
<b>Balance at May 31, 2024</b>	<b>28,536,132</b>	<b>5,730</b>	<b>966</b>		<b>9,857</b>	<b>16,554</b>

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Cash provided by (used in)</b>				
<b>Operating activities</b>				
Net loss	(421)	(218)	(225)	(378)
Non-cash items included in net earnings (loss)				
Realized gain on sale of financial instruments	-	-	(41)	-
Depreciation of property, plant and equipment	10	11	31	31
Depreciation of right-of-use assets	35	37	106	106
Amortization of intangible assets	51	51	152	146
Unrealized loss (gain) on financial instruments	120	389	112	625
Loss on disposal of property, plan and equipment	-	-	11	1
Share-based compensation (note 8)	7	24	96	55
Deferred tax expense	-	-	50	-
Finance income (note 9)	(114)	(183)	(394)	(534)
Changes in non-cash working capital (note 12)	265	(204)	62	(227)
<b>Net cashflows used in operating activities</b>	<b>(47)</b>	<b>(93)</b>	<b>(41)</b>	<b>(176)</b>
<b>Investing activities</b>				
Proceeds (purchase) of short term investment	(5,000)	-	2,781	(2,680)
Proceeds on sale of fixed income securities (note 7)	-	-	1,892	-
Proceeds on sale of marketable securities (note 6)	-	-	283	-
Finance income received (note 9)	114	183	394	534
Investment in intangible assets	(218)	(101)	(539)	(243)
Purchase of property, plant and equipment	(12)	(11)	(27)	(27)
<b>Net cashflows from (used in) investing activities</b>	<b>(5,116)</b>	<b>70</b>	<b>4,784</b>	<b>(2,415)</b>
<b>Financing activities</b>				
Repurchase of common shares (note 8)	(202)	-	(202)	-
Payment of lease obligation	(34)	(26)	(99)	(74)
<b>Net cashflows used in financing activities</b>	<b>(235)</b>	<b>(26)</b>	<b>(301)</b>	<b>(74)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(5,399)</b>	<b>(48)</b>	<b>4,442</b>	<b>(2,665)</b>
Cash and cash equivalents, beginning of period	13,133	7,155	3,292	9,771
<b>Cash and cash equivalents, end of period</b>	<b>7,734</b>	<b>7,107</b>	<b>7,734</b>	<b>7,107</b>

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

## 1. NATURE OF OPERATIONS

Titan Logix Corp. (the "Company") is a public company incorporated and domiciled in Canada and its common shares trade on the TSX Venture Exchange under the symbol TLA. The head office for the Company is located in Edmonton, Alberta, Canada. The address of the Company's registered office is #2600 10180 101 Street, Edmonton, AB T5J 3Y2.

For over 25 years, Titan Logix Corp. has designed and manufactured mobile liquid measurement solutions to help businesses reduce risk and maximize efficiencies in bulk liquids transportation. Titan's TD Series of tank level monitors are a market leader in mobile fluid measurement, and are known for their high level of accuracy, rugged design, and solid-state reliability. Our solutions are designed for hazardous and non-hazardous applications, and we serve customers in a wide range of applications including petroleum, environmental solutions, chemical, and agriculture.

## 2. BASIS OF PRESENTATION

### Statement of compliance

These unaudited condensed consolidated interim financial statements for the three- and nine- month periods ended May 31, 2025, and May 31, 2024, have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). They have been prepared in accordance with IAS 34, "Interim Financial Reporting" and do not contain all necessary annual disclosures in accordance with IFRS.

The unaudited condensed consolidated interim financial statements of the Company for the three- and nine- months ended May 31, 2025, were authorized for issue in accordance with a resolution of the directors on July 16, 2025.

### Principles of consolidation

These unaudited condensed consolidated interim financial statements include the financial statements of Titan Logix Corp. and its wholly owned subsidiary, Titan Logix USA Corp. The financial statements for the subsidiary are prepared for the same reporting period as the parent company using consistent accounting policies. All intercompany transactions and balances have been eliminated in the preparation of these unaudited condensed consolidated interim financial statements.

### Functional and presentation currency

The unaudited condensed consolidated interim financial statements are presented in Canadian dollars which is the functional currency of Titan Logix Corp. and its subsidiary.

### Comparative figures

Certain prior year balances have been reclassified to conform with current period presentation.

## 3. SIGNIFICANT ACCOUNTING POLICIES

These unaudited condensed consolidated interim financial statements, in all material respects, follow the same accounting policies and method of application as the annual audited consolidated financial statements of the preceding fiscal year. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the annual consolidated financial statements for the year ended August 31, 2024.

## 4. FINANCIAL INSTRUMENTS – FAIR VALUE MEASUREMENT

The Company's financial instruments consist of cash and cash equivalents, short term investments, accounts receivable, marketable securities, limited recourse capital notes, accounts payable and accrued liabilities and lease liabilities. The carrying amounts of the current financial assets and current financial liabilities recognized in the Company's consolidated financial statements at the end of the reporting period approximate their fair value due to their short period to maturity. Using the effective interest rate method, the fair value of the lease liability approximates the carrying value as the effective interest rates approximates the market interest rates. The fair value of the LRCNs was determined with reference to quoted market bids provided by a third-party independent dealer in the secondary market, as the LRCNs were not listed on any securities exchange. It was determined that broker pricing was appropriate for these investments as there was sufficient trading volume to demonstrate that the fair values quotes were appropriate. The Company no longer holds LRCNs.

## 5. CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

Cash and cash equivalents include the following components:

As at	May 31 2025 \$	August 31 2024 \$
Cash on hand and balances with banks	1,136	294
Guaranteed investment certificates (GICs) and other high interest deposits	11,598	10,779
<b>Total cash and equivalents and short term investments</b>	<b>12,734</b>	<b>11,073</b>
<b>Cash and equivalents</b>	<b>7,734</b>	<b>3,292</b>
<b>Short term investments</b>	<b>5,000</b>	<b>7,781</b>

Short term investments consist of guaranteed investment certificates (GICs) not cashable within three months of their acquisition. At May 31, 2025, \$5,000 of the GICs held by the Company were cashable after three months of their acquisition date, resulting in classification as short-term investments, GICs classified as cash and equivalents totalled \$6,598. GICs were invested at interest rates from 3.75% to 3.95% (2024 – 5.7% to 6.0%).

## 6. MARKETABLE SECURITIES

Marketable securities consist of shares of publicly traded companies and are reported at their fair market value. The Company's investments at fair market value are as follows:

	Number of Shares	May 31 2025 Fair Value \$	Number of Shares	August 31 2024 Fair Value \$
Bri-Chem Corp.	1,496,000	329	2,425,000	715
	<b>1,496,000</b>	<b>329</b>	<b>2,425,000</b>	<b>715</b>

On September 6, 2024, the Company sold 929,000 shares of Bri-Chem Corp. for \$0.305 per share for proceeds of \$283, resulting in a realized gain of \$9. For the nine months ended May 31, 2025, the Company recorded an unrealized loss of \$112 (2024 – unrealized loss – \$303) attributable to changes in the fair value of the shares of Bri-Chem Corp.

## 7. LIMITED RECOURSE CAPITAL NOTES

The Company's investment in limited recourse capital notes (LRCNs) are reported at their fair market value and are as follows:

	Number of units	May 31 2025 Fair Value \$	Number of units	August 31 2024 Fair Value \$
Limited recourse capital notes	-	-	1,900,000	1,861
	-	-	<b>1,900,000</b>	<b>1,861</b>

On January 24, 2025, the Company sold its entire LRCN position for gross proceeds \$1,892. During the year, the fair value of the LRCN position increased by \$32 up to the date of the sale, resulting in the Company realizing a gain of \$32 from the sale of the position in the current year.

**8. SHARE CAPITAL**
**Normal Course Issuer Bid (NCIB)**

On April 14<sup>th</sup>, the Company announced the commencement of a Normal Course Issuer Bid (NCIB). The NCIB, approved by the TSX Venture Exchange, allows the Company to repurchase up to 1,759,649 common shares representing approximately 10% of the public float of its issued and outstanding common shares over a 12-month period, ending on April 16, 2026. During the quarter ended May 31, 2025, the Company repurchased 274,000 common shares and cancelling 272,500 common shares under its NCIB program, at an average price of \$0.72 per share plus transaction costs, for a total cost of \$202. The excess of the purchase price over the stated capital of the shares repurchased, amounting to \$146, was charged to Retained Earnings.

**Stock Options**

On January 27, 2025, 50,000 stock options were exercised resulting in an additional 18,241 common shares being issued, bringing the total number of common shares issued and outstanding up to 28,554,373. On February 7, 2025, an additional 250,000 stock options were granted, vesting immediately at an exercise price of \$0.65 per share expiring on February 6, 2030. The fair value of the options granted was estimated on the grant date using the Black Scholes pricing model with the following weighted average assumptions; an expected life of 5 years, share volatility of 50.1% and a risk-free interest rate of 2.59%. The weighted average grant date value of \$0.30 per common share was estimated on February 7, 2025, using the Black Scholes Option Pricing Model.

At May 31, 2025, the Company has 1,500,000 options outstanding, which expire on dates between January 2027 and February 2030. Stock-based compensation of \$96 was recorded in the nine-months ended May 31, 2025 (2024 - \$55) of which \$7 was recorded in the current three-month period ended May 31, 2025 (2024 - \$24).

The continuity of the Company's outstanding and exercisable options is as follows:

	<b>May 31</b>		<b>August 31</b>	
	<b>2025</b>		<b>2024</b>	
	<b>Number of options outstanding #</b>	<b>Weighted average exercise price \$</b>	<b>Number of options outstanding #</b>	<b>Weighted average exercise price \$</b>
Outstanding, beginning of period	1,350,000	0.51	1,300,000	0.51
Granted	250,000	0.50	200,000	0.50
Forfeited	-	0.00	(150,000)	0.57
Exercised	(50,000)	0.49	-	0.00
<b>Outstanding, end of period</b>	<b>1,550,000</b>	<b>0.52</b>	<b>1,350,000</b>	<b>0.50</b>
<b>Exercisable, end of period</b>	<b>716,667</b>	<b>0.55</b>	<b>200,000</b>	<b>0.48</b>

The following table summarizes information about stock options outstanding and exercisable as at May 31, 2025:

Exercise price	<b>Options outstanding</b>	<b>Average remaining life (in years)</b>	<b>Options vested</b>	<b>Options not vested</b>
\$0.47	150,000	1.65	150,000	-
\$0.50	600,000	2.25	200,000	400,000
\$0.51	350,000	2.49	116,667	233,333
\$0.50	200,000	3.49	-	200,000
\$0.65	250,000	4.70	250,000	-
<b>Total, end of period</b>	<b>1,550,000</b>		<b>716,667</b>	<b>833,333</b>

## 9. FINANCE INCOME

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
Interest from investments in GICs and other high interest deposits	100	157	335	463
Interest from investments in LRCNs	-	21	38	61
Other interest income	13	5	22	10
	114	183	394	534

## 10. NATURE OF EXPENSES

The Company presents certain expenses in the Condensed Consolidated Statements of Earnings (Loss) and Comprehensive Earnings (Loss) by function. The following table presents these expenses by nature:

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Employee salaries and benefits</b>				
Included in cost of sales	(202)	(122)	(568)	(371)
Included in total expenses	(597)	(542)	(1,742)	(1,653)
<b>Total employee salaries and benefits</b>	<b>(799)</b>	<b>(664)</b>	<b>(2,310)</b>	<b>(2,024)</b>
<b>Depreciation and amortization</b>				
Included in cost of sales	(21)	(22)	(63)	(65)
Included in total expenses	(75)	(78)	(226)	(218)
<b>Total depreciation and amortization</b>	<b>(96)</b>	<b>(99)</b>	<b>(289)</b>	<b>(283)</b>

## 11. EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted earnings (loss) per share:

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Net loss</b>	<b>(421)</b>	<b>(218)</b>	<b>(225)</b>	<b>(378)</b>
Weighted average number of shares outstanding - basic	28,531,955	28,536,132	28,536,948	28,536,132
Effect of dilutive securities				
Stock options converted to common shares	-	-	-	-
<b>Weighted average number of shares outstanding - diluted</b>	<b>28,531,955</b>	<b>28,536,132</b>	<b>28,536,948</b>	<b>28,536,132</b>
Basic loss per share	(0.01)	(0.01)	(0.01)	(0.01)
Effect of dilutive securities	0.00	0.00	0.00	0.00
<b>Diluted earnings (loss) per share</b>	<b>(0.01)</b>	<b>(0.01)</b>	<b>(0.01)</b>	<b>(0.01)</b>

The average market value of the Company's shares for the purposes of any dilutive calculations are based on quoted market prices for the period during which the options were outstanding. For the nine-months ended May 31, 2025 and 2024, all options were anti-dilutive based on the net loss recorded for the period.

**12. CHANGE IN NON-CASH OPERATING WORKING CAPITAL**

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
Accounts receivable	233	(113)	498	(344)
Inventories	(173)	(190)	(556)	(25)
Prepaid expenses	18	73	110	126
Accounts payable and accrued liabilities	187	26	54	15
Income tax payable	-	-	(45)	-
	<b>265</b>	<b>(204)</b>	<b>62</b>	<b>(227)</b>

**13. RELATED PARTY TRANSACTIONS**

The Company did not have transactions with related parties in either the 2025 or 2024 fiscal periods ended. The Company's key management personnel include its directors and executive. Compensation to key management personnel of the Company for the period was as follows:

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
Salaries and short-term employee benefits	209	231	402	446
Share-based compensation	82	20	89	31
	<b>291</b>	<b>250</b>	<b>491</b>	<b>478</b>

**14. SEGMENTED REPORTING**

The Company operates substantially all its activities in one reportable segment, mobile liquid measurement solutions, which include the developing, manufacturing and marketing of mobile liquid measurement solutions. Operating segments are defined as components of the Company for which separate financial information is available that is evaluated regularly by the chief operating decision makers in allocating resources and assessing performance. The chief operating decision maker of the Company is the Chief Executive Officer.

Segmented information is provided on the basis of geographic segments as the Company sells into two primary geographic regions: Canada and the United States.

	Three months ended		Nine months ended	
	2025	2024	2025	2024
	\$	\$	\$	\$
Canada	628	562	1,910	1,639
United States and other	861	1,364	3,236	3,552
	<b>1,489</b>	<b>1,926</b>	<b>5,145</b>	<b>5,191</b>

For the nine months ended May 31, 2025, revenue from a single customer made up 13% of total revenue (2024 – 16%). At May 31, 2025, all non-current assets were held in Canada.

**Corporate Address:**

4130 – 93 Street NW  
Edmonton, Alberta, Canada T6E 5P5  
Phone: (780) 462-4085; Fax: (780) 450-8369

**Exchange Listing:**

The Toronto Venture Stock Exchange (TSX-V)  
Stock Symbol: TLA

**Investor Information:**

Investor Relations, Titan Logix Corp.  
4130 – 93 Street NW  
Edmonton, Alberta, Canada T6E 5P5  
Phone: (780) 462-4085; Fax: (780) 450-8369  
Email: [invest@titanlogix.com](mailto:invest@titanlogix.com)

**Transfer Agent:**

Computershare Investor Services Inc.  
Stock Transfer Services  
800, 324 – 8th Avenue SW, Calgary, Alberta, Canada  
T2P 2Z2  
Telephone: 1-800-564-6253

**Directors:**

**S. Grant Reeves, BA**  
Chair of the Board

**Helen Cornett, CPA, CA**  
Audit Committee Chair

**Victor Lee, B.Sc. Engineering, B.S. Computer Science**  
Executive Compensation and Corporate Governance  
Committee Chair

**Robert Tasker, B.A.Sc, Engineering, MBA**

**Officers:**

**Nicholas Forbes**  
Chief Executive Officer

**Michael Martin, CPA, CA**  
Chief Financial Officer

**Auditors:**

Kingston Ross Pasnak LLP

[www.titanlogix.com](http://www.titanlogix.com)